Sharemaestro company-news research for Bal Pharma Limited (BALPHARMA), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NSI
India
Provisional evidence
Company news sentiment
BALPHARMA news sentiment
Bal Pharma Limited
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score50Neutral is 50
Early balanced news score
17/100 evidence confidence
100% direct company focus
6 current stories across 3 publishers
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone42/100
→
Reliability-adjusted score50/100
Latest source headline
Bal Pharma opens 48-hour window for shareholder feedback on warrant pricing
scanx.trade · 07 Aug 2026 22:43 · Source lookup
Freshness, source quality and evidence depth temper uncertain readings toward 50; confidence remains a separate reliability measure.
What supports the score
6 current stories are mapped specifically to BALPHARMA.
The read spans 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.033.
Evidence confidence is 17/100, below the threshold for a firm classification.
50/100
News scoreEarly balanced news score
17/100
Confidencethin evidence
100%/100
Company news6 company stories
92/100
Story agreement8/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.033 after freshness weightingSource breadth60
3 independent publishersCompany relevance100
share tied directly to this companyFreshness11
recency-weighted evidenceAgreement92
how closely stories agreePublisher mix1
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202650INR 89.23+1.3%
31 Jul 202649INR 88.09+0.9%
24 Jul 202650INR 87.34+0.4%
17 Jul 202650INR 86.97+9.5%
10 Jul 202650INR 79.4+1.9%
03 Jul 202650INR 77.95-6.4%
26 Jun 202649INR 83.27-4.1%
Provisional evidence
News subjects
What is shaping the score
Market update504 stories · 67%
Earnings341 stories · 17%
Regulatory and legal501 stories · 17%
Source mix
Where the evidence comes from
scanx.trade433 stories · 50%
MarketsMojo502 stories · 33%
TipRanks501 stories · 17%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral13 Aug 16:32
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 16:32 | 50 | +0 | 16/100 (-8) | 6 (-1) | Provisional |
| 07 Aug 23:59 | 50 | +2 | 24/100 (-6) | 7 (+1) | Provisional |
| 27 Jul 23:59 | 48 | -2 | 30/100 (+1) | 6 (+2) | Provisional |
| 23 Jul 23:59 | 50 | +0 | 29/100 (+1) | 4 (+1) | Provisional |
| 22 Jul 23:59 | 50 | +0 | 28/100 (+2) | 3 (-1) | Provisional |
| 15 Jul 23:59 | 50 | +0 | 26/100 (+1) | 4 (+1) | Provisional |
| 09 Jul 23:59 | 50 | +2 | 25/100 (-2) | 3 (+1) | Provisional |
| 22 Jun 23:59 | 48 | +0 | 27/100 (0) | 2 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
scanx.tradeDirect company coverageScored from headlineSource lookup
Bal Pharma opens 48-hour window for shareholder feedback on warrant pricing
- Published
- 07 Aug 2026 22:43
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- High · 21.9% · 5.7d old
- Duplicates
- 1 consolidated
#250Tone
TipRanksDirect company coverageScored from headlineSource lookup
Bal Pharma Rectifies Technical Discrepancies in NSE XBRL Filings
- Published
- 27 Jul 2026 13:12
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.5% · 17.1d old
- Duplicates
- 1 consolidated
#334Tone
scanx.tradeDirect company coverageScored from headlineSource lookup
Bal Pharma Q4 Results: Net profit falls 34% YoY to ₹370 lakh
- Published
- 27 Jul 2026 07:00
- News subject
- Earnings
- Why this score
- Operating deterioration
- How it is used
- Direct company coverage
- Weighted influence
- High · 46.3% · 17.4d old
- Duplicates
- 2 consolidated
#450Tone
MarketsMojoDirect company coverageScored from headlineSource lookup
Bal Pharma Ltd Valuation Shifts to Very Attractive Amid Sector Challenges
- Published
- 23 Jul 2026 21:35
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.1% · 20.8d old
- Duplicates
- 1 consolidated
#550Tone
scanx.tradeDirect company coverageScored from headlineSource lookup
Bal Pharma seeks approval to issue warrants to promoter
- Published
- 22 Jul 2026 08:20
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- High · 31.1% · 22.3d old
- Duplicates
- 2 consolidated
#657Tone
MarketsMojoDirect company coverageScored from headlineSource lookup
Bal Pharma Ltd Valuation Improves as Price Attractiveness Shifts Amid Sector Challenges
- Published
- 15 Jul 2026 10:41
- News subject
- Market update
- Why this score
- Positive financial language
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 29.2d old
- Duplicates
- 1 consolidated
Earlier company news
BALPHARMA news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above. Where an early legacy import did not retain its canonical URL, the headline links to an exact publisher-aware source lookup instead of inventing an article address.
Jul
19
2026
WhalesbookArchivedLegacy headline · tone unscoredLegacy source lookup
Bal Pharma to Issue Warrants to Promoter, Raise ₹8.1 Cr
- Published
- 19 Jul 2026 13:59
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
09
2026
Stock TitanArchivedLegacy headline · tone unscoredLegacy source lookup
If You Invested $1,000 in Innocan Pharma (INNPF)
- Published
- 9 Jul 2026 04:18
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
EquitymasterArchivedLegacy headline · tone unscoredLegacy source lookup
Compare with BAL PHARMA
- Published
- 22 Jun 2026 20:31
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
21
2026
MarketsMojoArchivedLegacy headline · tone unscoredLegacy source lookup
Bal Pharma Ltd Downgraded to Sell Amidst Flat Financials and Weak Fundamentals
- Published
- 21 Jun 2026 01:02
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.